Histamine H3 receptor (H3R) antagonists/inverse agonists have revealed potential to treat diverse disease states of the central nervous system (CNS) including Alzheimer's disease (AD), attention-deficit hyperactivity syndrome (ADHD), schizophrenia, obesity, pain, epilepsy, narcolepsy, substance abuse, etc. (Leurs et al., 2011; Passani and Blandina, 2011). This evidence concerns the gene HRH3 and obesity due to melanocortin 4 receptor deficiency.